NO321048B1 - Medisinsk preparat og anvendelse derav til fremstilling av et topisk barrieremateriale, et UV-straleabsorberende materiale, eller et middel mot virus, sopp eller betennelser - Google Patents
Medisinsk preparat og anvendelse derav til fremstilling av et topisk barrieremateriale, et UV-straleabsorberende materiale, eller et middel mot virus, sopp eller betennelser Download PDFInfo
- Publication number
- NO321048B1 NO321048B1 NO19992841A NO992841A NO321048B1 NO 321048 B1 NO321048 B1 NO 321048B1 NO 19992841 A NO19992841 A NO 19992841A NO 992841 A NO992841 A NO 992841A NO 321048 B1 NO321048 B1 NO 321048B1
- Authority
- NO
- Norway
- Prior art keywords
- chitosan
- formulation
- accordance
- skin
- acid
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 50
- 230000004888 barrier function Effects 0.000 title claims description 48
- 230000000699 topical effect Effects 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title claims description 13
- 241000233866 Fungi Species 0.000 title claims description 6
- 241000700605 Viruses Species 0.000 title claims description 6
- 206010061218 Inflammation Diseases 0.000 title description 6
- 230000004054 inflammatory process Effects 0.000 title description 6
- 239000011358 absorbing material Substances 0.000 title description 2
- 229920001661 Chitosan Polymers 0.000 claims abstract description 102
- 229920000642 polymer Polymers 0.000 claims abstract description 70
- 239000000126 substance Substances 0.000 claims abstract description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 125000002091 cationic group Chemical group 0.000 claims abstract description 36
- 125000000129 anionic group Chemical group 0.000 claims abstract description 35
- 239000002516 radical scavenger Substances 0.000 claims abstract description 23
- -1 anionic ethyleneamine compounds Chemical class 0.000 claims abstract description 18
- 150000001412 amines Chemical class 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 14
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 5
- 108010055896 polyornithine Proteins 0.000 claims abstract description 4
- 229920002714 polyornithine Polymers 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 129
- 238000009472 formulation Methods 0.000 claims description 119
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 55
- 239000006071 cream Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 43
- 239000013566 allergen Substances 0.000 claims description 33
- 230000004224 protection Effects 0.000 claims description 33
- 229920002873 Polyethylenimine Polymers 0.000 claims description 25
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- 230000001681 protective effect Effects 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 19
- 239000002085 irritant Substances 0.000 claims description 18
- 231100000021 irritant Toxicity 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 230000000840 anti-viral effect Effects 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000000843 anti-fungal effect Effects 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 206010012442 Dermatitis contact Diseases 0.000 claims description 12
- 208000010247 contact dermatitis Diseases 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 239000002674 ointment Substances 0.000 claims description 11
- 229960003080 taurine Drugs 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000009889 Herpes Simplex Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 239000002207 metabolite Substances 0.000 claims description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims description 7
- 229960003151 mercaptamine Drugs 0.000 claims description 7
- 229920000768 polyamine Polymers 0.000 claims description 7
- 150000003141 primary amines Chemical class 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 6
- 241000130764 Tinea Species 0.000 claims description 6
- 229960004308 acetylcysteine Drugs 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000003573 thiols Chemical group 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000002474 Tinea Diseases 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 4
- BTSHXVLJDRJCMM-UHFFFAOYSA-N 3-(4-aminobutylamino)propanoic acid Chemical compound NCCCCNCCC(O)=O BTSHXVLJDRJCMM-UHFFFAOYSA-N 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- DGMOQCHIPOPXEK-UHFFFAOYSA-N Spermic acid 2 Chemical compound OC(=O)CCNCCCCNCCC(O)=O DGMOQCHIPOPXEK-UHFFFAOYSA-N 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229930009674 sesquiterpene lactone Natural products 0.000 claims description 4
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 claims description 4
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 4
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims description 3
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims description 3
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 claims description 3
- CFKQGOZERLOGSM-UHFFFAOYSA-N [2-[bis[[hydroxy(methoxy)phosphoryl]oxy]amino]ethyl-[hydroxy(methoxy)phosphoryl]oxyamino] methyl hydrogen phosphate Chemical compound COP(O)(=O)ON(OP(O)(=O)OC)CCN(OP(O)(=O)OC)OP(O)(=O)OC CFKQGOZERLOGSM-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 claims description 3
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 claims description 2
- HHDUMDVQUCBCEY-UHFFFAOYSA-N 4-[10,15,20-tris(4-carboxyphenyl)-21,23-dihydroporphyrin-5-yl]benzoic acid Chemical compound OC(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc([nH]2)c(-c2ccc(cc2)C(O)=O)c2ccc(n2)c(-c2ccc(cc2)C(O)=O)c2ccc1[nH]2 HHDUMDVQUCBCEY-UHFFFAOYSA-N 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 150000007513 acids Chemical class 0.000 abstract description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 121
- 210000003491 skin Anatomy 0.000 description 89
- 229910052759 nickel Inorganic materials 0.000 description 60
- 229960003330 pentetic acid Drugs 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 32
- 238000012360 testing method Methods 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229910052751 metal Inorganic materials 0.000 description 24
- 239000002184 metal Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 23
- 239000000499 gel Substances 0.000 description 22
- 230000002009 allergenic effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000005855 radiation Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 201000004624 Dermatitis Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 239000002738 chelating agent Substances 0.000 description 17
- 208000010668 atopic eczema Diseases 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229910021645 metal ion Inorganic materials 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000516 sunscreening agent Substances 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 239000006096 absorbing agent Substances 0.000 description 10
- 231100000321 erythema Toxicity 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 235000011121 sodium hydroxide Nutrition 0.000 description 10
- 230000000475 sunscreen effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229920006317 cationic polymer Polymers 0.000 description 6
- 229910017052 cobalt Inorganic materials 0.000 description 6
- 239000010941 cobalt Substances 0.000 description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 5
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 241000003910 Baronia <angiosperm> Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000004904 UV filter Substances 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000008139 complexing agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910001453 nickel ion Inorganic materials 0.000 description 4
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000005714 Chitosan hydrochloride Substances 0.000 description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000159241 Toxicodendron Species 0.000 description 3
- 241000159243 Toxicodendron radicans Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000002029 allergic contact dermatitis Diseases 0.000 description 3
- 229960004050 aminobenzoic acid Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 3
- 229960005228 clioquinol Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000001875 irritant dermatitis Diseases 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010058898 Hand dermatitis Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010043870 Tinea infections Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 2
- 231100000567 intoxicating Toxicity 0.000 description 2
- 230000002673 intoxicating effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- CAAULPUQFIIOTL-UHFFFAOYSA-L methyl phosphate(2-) Chemical compound COP([O-])([O-])=O CAAULPUQFIIOTL-UHFFFAOYSA-L 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920002851 polycationic polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 229960001124 trientine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- FGTYTUFKXYPTML-UHFFFAOYSA-N 2-benzoylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 FGTYTUFKXYPTML-UHFFFAOYSA-N 0.000 description 1
- XMMODWGMKHUZQW-UHFFFAOYSA-N 2-hydroxy-16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCC(O)C(O)=O XMMODWGMKHUZQW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- RBDYMRWHRDPLOS-UHFFFAOYSA-N 4-(dimethylamino)-3-ethyl-2-hexylbenzoic acid Chemical compound CCCCCCC1=C(CC)C(N(C)C)=CC=C1C(O)=O RBDYMRWHRDPLOS-UHFFFAOYSA-N 0.000 description 1
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000011675 Skin degenerative disease Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- BZUIJMCJNWUGKQ-BDAKNGLRSA-N hypusine Chemical compound NCC[C@@H](O)CNCCCC[C@H](N)C(O)=O BZUIJMCJNWUGKQ-BDAKNGLRSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- RJMMFJHMVBOLGY-UHFFFAOYSA-N indium(3+) Chemical compound [In+3] RJMMFJHMVBOLGY-UHFFFAOYSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000010721 machine oil Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940073644 nickel Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Birds (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604610A SE9604610D0 (sv) | 1996-12-16 | 1996-12-16 | Medical composition |
| PCT/SE1997/002126 WO1998026788A1 (en) | 1996-12-16 | 1997-12-16 | Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992841D0 NO992841D0 (no) | 1999-06-11 |
| NO992841L NO992841L (no) | 1999-08-16 |
| NO321048B1 true NO321048B1 (no) | 2006-03-06 |
Family
ID=20404983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992841A NO321048B1 (no) | 1996-12-16 | 1999-06-11 | Medisinsk preparat og anvendelse derav til fremstilling av et topisk barrieremateriale, et UV-straleabsorberende materiale, eller et middel mot virus, sopp eller betennelser |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6562802B2 (pl) |
| EP (1) | EP0957927B1 (pl) |
| JP (1) | JP4703792B2 (pl) |
| KR (1) | KR20000069521A (pl) |
| CN (1) | CN1245431A (pl) |
| AT (1) | ATE288760T1 (pl) |
| AU (1) | AU720008B2 (pl) |
| CA (1) | CA2275321C (pl) |
| CZ (1) | CZ295459B6 (pl) |
| DE (1) | DE69732495T2 (pl) |
| ES (1) | ES2236837T3 (pl) |
| HK (1) | HK1022644A1 (pl) |
| HU (1) | HUP0000557A3 (pl) |
| NO (1) | NO321048B1 (pl) |
| NZ (1) | NZ336313A (pl) |
| PL (1) | PL191316B1 (pl) |
| RO (1) | RO120122B1 (pl) |
| SE (1) | SE9604610D0 (pl) |
| WO (1) | WO1998026788A1 (pl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1139981A4 (en) * | 1998-12-24 | 2002-04-17 | Four Star Partners | COMPOSITIONS AND RELATED METHODS OF USE |
| EP1237535A1 (en) * | 1999-12-17 | 2002-09-11 | The Procter & Gamble Company | Compositions for efficient release of active ingredients |
| JP2003524635A (ja) * | 1999-12-23 | 2003-08-19 | アイヴリア インコーポレイテッド | 活性作用物の局所デリバリー用キトサンバイオポリマー |
| JP4771502B2 (ja) * | 2000-06-13 | 2011-09-14 | 住化エンビロサイエンス株式会社 | 抗アレルゲン組成物及びアレルゲン不活化方法 |
| DE10035991A1 (de) | 2000-07-24 | 2002-02-14 | Polichem Sa | Nagellackzusammensetzung |
| GB0019283D0 (en) * | 2000-08-04 | 2000-09-27 | Novartis Ag | Organic compounds |
| CN1258353C (zh) * | 2000-09-11 | 2006-06-07 | 庄臣及庄臣有限公司 | 美容和药用组合物以及其应用 |
| US20040052826A1 (en) * | 2000-09-11 | 2004-03-18 | Elena Fernandez-Kleinlein | Cosmetic and pharmaceutical compositions and their use |
| GB0024489D0 (en) * | 2000-10-06 | 2000-11-22 | Reckitt Benckiser Uk Ltd | Improvements in or relating to organic compositions |
| EP1343492B1 (en) * | 2000-11-22 | 2006-02-01 | Rxkinetix, Inc. | Treatment of mucositis |
| KR100423666B1 (ko) * | 2001-02-07 | 2004-03-18 | 보령제약 주식회사 | 항진균 외용 제제 |
| US7998699B2 (en) | 2002-08-15 | 2011-08-16 | University Of South Florida | Early detection of pathogens in blood |
| CN100453121C (zh) * | 2002-11-12 | 2009-01-21 | 吴奕光 | 一种医用敷料及其生产方法 |
| EP1438954A1 (de) * | 2003-01-18 | 2004-07-21 | Beiersdorf AG | Erhöhung der Thermostabilität und Verbesserung der Fliesseigenschaften von chitosanhaltigen Formulierungen |
| GB2398497A (en) * | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
| EP2112232B1 (en) | 2003-08-15 | 2014-04-23 | University of South Florida | Methods for extracting pathogen nucleic acid from a blood sample using aurintricarboxylic acid |
| US20050283004A1 (en) | 2004-06-18 | 2005-12-22 | Hopax Chemicals Manufacturing Co., Ltd. | Alkylsulfonated polyaminosaccharides |
| US20100239655A1 (en) * | 2004-12-09 | 2010-09-23 | Georgia Levis | Taurine-based compositions and therapeutic methods |
| US20060127342A1 (en) * | 2004-12-09 | 2006-06-15 | Georgia Levis | Taurine-based compositions, therapeutic methods, and assays |
| US7691830B2 (en) * | 2005-02-17 | 2010-04-06 | Clive Elson | Method and composition for treatment of a mucosal tissue disorder |
| US7311050B2 (en) * | 2005-04-19 | 2007-12-25 | Kamterter Ii, L.L.C. | Systems for the control and use of fluids and particles |
| AU2006320538B2 (en) * | 2005-11-30 | 2013-07-04 | Endo Pharmaceuticals Inc. | Treatment of xerostomia with a sulfur-containing antioxidant |
| ATE475424T1 (de) * | 2006-04-04 | 2010-08-15 | Marinomed Biotechnologie Gmbh | Cellulosesulfat zur behandlung von rhinovirus- infektionen |
| WO2007129330A1 (en) * | 2006-05-05 | 2007-11-15 | Blaa Lonid Hf. | Pharmaceutical and cosmetic use of silica |
| US7964002B2 (en) | 2006-06-14 | 2011-06-21 | Chemtura Corporation | Antioxidant additive for biodiesel fuels |
| EP1958639A1 (en) * | 2007-02-14 | 2008-08-20 | Polichem S.A. | Use of chitosans for the treatment of nail inflammatory diseases |
| US10201490B2 (en) | 2007-02-14 | 2019-02-12 | Polichem Sa | Use of chitosans for the treatment of nail inflammatory diseases |
| EP1958613A1 (en) * | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| DE112008000888T5 (de) | 2007-04-04 | 2011-05-19 | Hugh Birchwood McTavish | Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen |
| US20090004288A1 (en) * | 2007-06-29 | 2009-01-01 | Collins Gary L | Stabilized ophthalmic solutions |
| US8131278B2 (en) * | 2008-12-05 | 2012-03-06 | Nokia Corporation | Method, apparatus, and computer program product for application-based communications |
| JP2012521357A (ja) * | 2009-03-19 | 2012-09-13 | ケントン・ダブリュー・グレゴリー | 対策用方法および装置 |
| WO2010109421A1 (en) * | 2009-03-25 | 2010-09-30 | Sulur Subramaniam Vanangamudi | A medicinal antifungal and steroids cream comprising chitosan and a process to make it |
| US20120040927A1 (en) * | 2009-04-20 | 2012-02-16 | Apex Laboratories Private Limited | Medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it. |
| US20120115828A1 (en) * | 2009-04-20 | 2012-05-10 | Apex Laboratories Private Limited | Medicinal cream containing miconazole nitrate, hydrocortisone acetate, and a biopolymer, and a process to make it |
| EP2482807A4 (en) | 2009-10-02 | 2013-04-24 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR PROPHYLAXIS FOR CONTACT ECZEMA |
| US20110225809A1 (en) * | 2010-03-17 | 2011-09-22 | Alan Francis Daher | Apparatus for removably attaching an item to a surface |
| CN103479400A (zh) * | 2012-06-11 | 2014-01-01 | 浙江我武生物科技股份有限公司 | 一种含有漆酚的皮炎诊断贴剂及其制备方法 |
| FR2993466B1 (fr) * | 2012-07-18 | 2014-08-15 | Prevor Internat | Utilisation d'une creme de protection contre les effets des agents chimiques agressifs en contact avec la peau |
| US20150209275A1 (en) * | 2012-09-11 | 2015-07-30 | University Of The Witwatersrand, Johannesburg | Fast Dissolving Ocular Insert |
| CN103951763B (zh) * | 2014-04-22 | 2016-06-22 | 大连民族学院 | O-烷基氨基甲酸酯壳聚糖、转基因复合物微粒及其制备方法 |
| JP6742312B2 (ja) | 2014-08-05 | 2020-08-19 | アマンタン・エクスペール | 皮膚保護組成物 |
| CN107427540A (zh) | 2015-02-26 | 2017-12-01 | 斯垮瑞斯有限责任公司 | 用于治疗单纯疱疹病毒感染的非特异性延迟型过敏反应 |
| PT3124016T (pt) * | 2015-07-31 | 2019-12-13 | Univ Warszawski Medyczny | Composição de emulsão antipsoriática que compreende cefazolina |
| JP2018184362A (ja) * | 2017-04-25 | 2018-11-22 | 株式会社Ｒ−ｇｏｏｄ | 殺菌性組成物 |
| CN107973866B (zh) * | 2017-12-15 | 2020-08-28 | 武汉工程大学 | 具有高的sod酶活性的四氮大环锰配合物修饰壳聚糖复合材料及其制备方法 |
| CN108892743A (zh) * | 2018-05-28 | 2018-11-27 | 南京工业大学 | 用于光动力抗菌的纳米光敏剂，其制备方法及应用 |
| CN115177738A (zh) * | 2022-05-07 | 2022-10-14 | 中国人民解放军陆军军医大学第一附属医院 | 一种促进核素排泄的乙二醇壳聚糖dtpa及其制备方法 |
| WO2024013711A1 (en) | 2022-07-15 | 2024-01-18 | Universidade De Coimbra | Topical composition and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1027501B (it) * | 1968-12-06 | 1978-12-20 | Muzzarelli Weckx M G F | Chitina chitosano e derivati usati come supporti cromatografici e come adsorbenti per la raccolta di ioni dalle soluzuoni acquose e organiche dall acqua potabile e marina |
| US4031025A (en) * | 1971-05-10 | 1977-06-21 | Societe Anonyme Dite: L'oreal | Chitosan derivative, sequestering agents for heavy metals |
| US3879376A (en) * | 1971-05-10 | 1975-04-22 | Oreal | Chitosan derivative, method of making the same and cosmetic composition containing the same |
| US4382864A (en) * | 1980-08-08 | 1983-05-10 | Kurita Water Industries Ltd. | Process for dewatering sludges |
| DE3245784A1 (de) * | 1982-12-10 | 1984-06-14 | Wella Ag, 6100 Darmstadt | Kosmetisches mittel auf der basis von quaternaeren chitosanderivaten, neue quaternaere chitosanderivate sowie verfahren zu ihrer herstellung |
| US5000945A (en) * | 1986-04-22 | 1991-03-19 | Ajinomoto Co., Inc. | Method of stabilizing a UVB absorbing compound, a stabilized UV absorber, and a cosmetic composition containing the same |
| US4929722A (en) * | 1986-06-06 | 1990-05-29 | Union Carbide Chemicals And Plastics Company Inc. | Acid decrystallization of aminopolysaccharides and derivatives thereof |
| US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| JPH0696489B2 (ja) * | 1987-05-11 | 1994-11-30 | 株式会社資生堂 | 皮膚および毛髪用組成物 |
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
| US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
| WO1992009636A1 (en) * | 1990-11-30 | 1992-06-11 | Baker Cummins Dermatologicals, Inc. | Skin protective compositions and method of inhibiting skin irritation |
| US5348799A (en) * | 1991-09-03 | 1994-09-20 | Minnesota Mining And Manufacturing Company | Antistatic coatings comprising chitosan acid salt and metal oxide particles |
| JPH07196468A (ja) * | 1993-12-30 | 1995-08-01 | Sansho Seiyaku Co Ltd | 化粧料 |
| TW460296B (en) * | 1994-09-01 | 2001-10-21 | Janssen Pharmaceutica Nv | Topical ketoconazole emulsion compositions without sodium sulfite |
| SE9403138L (sv) | 1994-09-20 | 1996-03-21 | Asea Brown Boveri | Manöverdon för brytare |
| US5698476A (en) * | 1995-03-01 | 1997-12-16 | The Clorox Company | Laundry article for preventing dye carry-over and indicator therefor |
| US5576013A (en) * | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
| US5646221A (en) * | 1995-03-31 | 1997-07-08 | Kowa Co., Ltd. | Adhesive base material |
| TW427912B (en) * | 1996-12-20 | 2001-04-01 | Kao Corp | Detergent composition |
| US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6019990A (en) * | 1997-11-21 | 2000-02-01 | Natural Nutrition Ltd. As | Conjugated linoleic acid delivery system in cosmetic preparations |
-
1996
- 1996-12-16 SE SE9604610A patent/SE9604610D0/xx unknown
-
1997
- 1997-12-16 PL PL333915A patent/PL191316B1/pl unknown
- 1997-12-16 ES ES97951368T patent/ES2236837T3/es not_active Expired - Lifetime
- 1997-12-16 AU AU55027/98A patent/AU720008B2/en not_active Expired
- 1997-12-16 EP EP97951368A patent/EP0957927B1/en not_active Expired - Lifetime
- 1997-12-16 KR KR1019997005424A patent/KR20000069521A/ko not_active Application Discontinuation
- 1997-12-16 DE DE69732495T patent/DE69732495T2/de not_active Expired - Lifetime
- 1997-12-16 AT AT97951368T patent/ATE288760T1/de not_active IP Right Cessation
- 1997-12-16 CZ CZ19992135A patent/CZ295459B6/cs not_active IP Right Cessation
- 1997-12-16 JP JP52761998A patent/JP4703792B2/ja not_active Expired - Lifetime
- 1997-12-16 WO PCT/SE1997/002126 patent/WO1998026788A1/en active IP Right Grant
- 1997-12-16 RO RO99-00675A patent/RO120122B1/ro unknown
- 1997-12-16 NZ NZ336313A patent/NZ336313A/en not_active IP Right Cessation
- 1997-12-16 CN CN97181506A patent/CN1245431A/zh active Pending
- 1997-12-16 CA CA002275321A patent/CA2275321C/en not_active Expired - Lifetime
- 1997-12-16 HU HU0000557A patent/HUP0000557A3/hu unknown
-
1999
- 1999-06-11 NO NO19992841A patent/NO321048B1/no not_active IP Right Cessation
- 1999-06-16 US US09/334,264 patent/US6562802B2/en not_active Expired - Lifetime
-
2000
- 2000-03-21 HK HK00101714A patent/HK1022644A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245431A (zh) | 2000-02-23 |
| NO992841L (no) | 1999-08-16 |
| CZ295459B6 (cs) | 2005-08-17 |
| WO1998026788A1 (en) | 1998-06-25 |
| AU720008B2 (en) | 2000-05-18 |
| CA2275321C (en) | 2009-02-03 |
| JP4703792B2 (ja) | 2011-06-15 |
| EP0957927A1 (en) | 1999-11-24 |
| RO120122B1 (ro) | 2005-09-30 |
| NZ336313A (en) | 2000-01-28 |
| EP0957927B1 (en) | 2005-02-09 |
| NO992841D0 (no) | 1999-06-11 |
| ATE288760T1 (de) | 2005-02-15 |
| ES2236837T3 (es) | 2005-07-16 |
| US20020128310A1 (en) | 2002-09-12 |
| KR20000069521A (ko) | 2000-11-25 |
| AU5502798A (en) | 1998-07-15 |
| DE69732495D1 (de) | 2005-03-17 |
| CZ213599A3 (cs) | 1999-11-17 |
| PL191316B1 (pl) | 2006-04-28 |
| CA2275321A1 (en) | 1998-06-25 |
| SE9604610D0 (sv) | 1996-12-16 |
| HUP0000557A2 (hu) | 2000-06-28 |
| US6562802B2 (en) | 2003-05-13 |
| JP2001506649A (ja) | 2001-05-22 |
| DE69732495T2 (de) | 2006-01-05 |
| HK1022644A1 (en) | 2000-08-18 |
| HUP0000557A3 (en) | 2001-11-28 |
| PL333915A1 (en) | 2000-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU720008B2 (en) | Medical composition and use thereof for the manufacture of topical barrier formulation, a UV-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation | |
| JP2000501429A (ja) | 局所治療用および化粧用製剤の組成物基剤 | |
| EP1888024B1 (en) | Topical compositions | |
| CA3013477A1 (en) | Moisturizing compositions and uses thereof | |
| WO1996023490A1 (en) | Formulations and methods for reducing skin irritation | |
| WO1996023490A9 (en) | Formulations and methods for reducing skin irritation | |
| KR20010043619A (ko) | 해수가 함유된 약제용, 위생용 및/또는 화장용 조성물 및이의 용도 | |
| US5098717A (en) | Method of treatment for pruritus | |
| WO2017143421A1 (pt) | Sistema nanométrico de liberação prolongada de ativos cosméticos e/ou repelentes | |
| WO1992009636A1 (en) | Skin protective compositions and method of inhibiting skin irritation | |
| Ceilley | Advances in topical delivery systems in acne: new solutions to address concentration dependent irritation and dryness | |
| WO2016030609A1 (fr) | Composition antimicrobienne | |
| JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
| CA2569234A1 (en) | Composition for treatment of a hydrofluoric acid burn | |
| WO2012049453A2 (en) | Compositions for topical applications | |
| GB2456528A (en) | Transition metal pyrrolidone carboxylic acids (PCA) as antioxidants in cosmetic preparations | |
| US20220378747A1 (en) | Topical composition for treating skin wounds | |
| KR20210015395A (ko) | 피부 자극을 감소시키기 위한 제제 및 방법 | |
| UA82472C2 (uk) | Трансдермальна фармацевтична композиція, що містить ацетилсаліцилову кислоту, для лікування кальцифікації | |
| JP2001322932A (ja) | 活性酸素消去剤及びこれを含有してなる活性酸素消去用の組成物 | |
| US20170354624A1 (en) | Topical compositions for treatment of skin irritation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |